Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial: Metabolic and Immunologic Features at Baseline Identify a Subgroup of Responders

Trials of immune therapies in new-onset type 1 diabetes (T1D) have shown success, but not all subjects respond, and the duration of response is limited. Our aim was to determine whether two courses of teplizumab, an Fc receptor–nonbinding anti-CD3 monoclonal antibody, reduces the decline in C-peptid...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Herold, Kevan C., Gitelman, Stephen E., Ehlers, Mario R., Gottlieb, Peter A., Greenbaum, Carla J., Hagopian, William, Boyle, Karen D., Keyes-Elstein, Lynette, Aggarwal, Sudeepta, Phippard, Deborah, Sayre, Peter H., McNamara, James, Bluestone, Jeffrey A.
Formato: Artigo
Idioma:Inglês
Publicado em: American Diabetes Association 2013
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3806618/
https://ncbi.nlm.nih.gov/pubmed/23835333
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/db13-0345
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados